Genmab
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 15
- Registration Number
- NCT05206357
- Locations
- 🇨🇿
Fakultnà Nemocnice Brno - Jihlavská /ID# 239956, Brno, Brno-mesto, Czechia
🇺🇸Lucile Packard Children's Hospital /ID# 240854, Palo Alto, California, United States
🇺🇸Nicklaus Children's Hospital /ID# 241174, Miami, Florida, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
Tianjin Cancer Hospital /ID# 228135, Tianjin, Tianjin, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
GEN1047 for Solid Tumors - First in Human (FIH) Trial
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 179
- Registration Number
- NCT05180474
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇺🇸UCLA Department of Medicine Hematology Oncology, Los Angeles, California, United States
🇺🇸Yale University - Yale Cancer Center, New Haven, Connecticut, United States
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genmab
- Target Recruit Count
- 125
- Registration Number
- NCT05117242
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸MD Anderson Cancer Center, Madrid, Spain
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genmab
- Target Recruit Count
- 18
- Registration Number
- NCT04937153
- Locations
- 🇯🇵
National Cancer Center East, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Genmab
- Target Recruit Count
- 252
- Registration Number
- NCT04824794
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, New Zealand
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- Conditions
- Interventions
- Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug: rituximab and lenalidomideDrug: rituximab and bendamustineDrug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatinDrug: gemcitabine and oxaliplatinDrug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisoneDrug: rituximab, ifosfamide, carboplatin, and etoposide phosphateDrug: LenalidomideBiological: Epcoritamab
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Genmab
- Target Recruit Count
- 543
- Registration Number
- NCT04663347
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 552
- Registration Number
- NCT04628494
- Locations
- 🇺🇸
Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸TriHealth Cancer Institute- Good Samaritan Hospital, Cincinnati, Ohio, United States
🇨🇳Beijing Cancer Hospital, Beijing, China
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT04623541
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 102
- Registration Number
- NCT04542824
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima-shi, Japan
🇯🇵National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan